Antisoma Share Discussion Threads

[davenic] 18/11/2008 09:05

Nice update and like this bit

"Positive outlook
With our expanded and well-funded pipeline, we look forward to
reporting a wealth of new data over the short and medium term. We
believe that, with a number of products now in late-stage
development, we are primed to make the transition from being a
development company to being a company that both develops and
commercialises novel cancer drugs"

[davenic] 10/11/2008 12:02

These are creeping up nicely each day about time (-:

[bluechef] 03/11/2008 20:52

Someone get out and push. This is like pulling teeth.

[davenic] 01/11/2008 12:33

patience (-:

[kamukak] 30/10/2008 14:14

funny enough this one doesn't move. are we expecting any news from any front for this company in next month? They do have a very strong balance sheet but seems like no one is intrested in them?

[bluechef] 28/10/2008 15:49

This is looking bleek. Evey sell ticking down but not the other way round. One of the better posistioned biotechs in my my opinion. Got to be bargain time surely.

[davenic] 28/10/2008 15:04

About time these moved up

[finkie] 20/10/2008 12:27

What is the companys net cash position currently please it says 2 pence on here which is only a couple of million!!

cheers

[abergele] 20/10/2008 09:34

Any thoughts on those larger trades @8-59.am.

sure as heck, if we put 600K+ of shares for sale ,the m/m's would only be giving you 19p??

[gnomet2] 18/10/2008 15:23

nmkniight - thanks. Yes, ASM is my favourite on a medium term basis.
It certainly looks very undervalued. Their lung cancer drug is meant to be more benign and maybe more effective than the blockbuster avastin, and Novartis is obviously very confident about it to have entered it into a second hugely expensive phase III trial at this stage - yet the market is only according it
an enterprise value of about 10 mill quid. (Market cap minus cash, Xanthus purchase,and its home grown phase II products).

[nmknight] 18/10/2008 12:33

ARTICLE IN THIS WEEKS SHARES MAG SIGHTS ANTISOMA AS BEST PICK FOR BIO COMPANIES
STATING ROYALTY TURNOVER AROUND £100M BY 2013 PLUS REVENUE FROM OWN SALES.(IF NOT SWALLOWED UP BY NAVARTIS BY THEN).

[davenic] 14/10/2008 12:29

Our time will come

[bluechef] 09/10/2008 09:57

Pretty poor this, not even bouncing with the markets up.

[davenic] 07/10/2008 08:24

Antisoma and The Institute of Cancer Research to collaborate on novel
approach to cancer treatment




London, UK, and Cambridge, MA: 7 October 2008: Cancer drug developer
Antisoma (LSE: ASM; USOTC: ATSMY), The Institute of Cancer Research
(The Institute) and Cancer Research Technology (CRT) today announced
a collaboration and licensing agreement under which Antisoma has
acquired rights to develop and commercialise novel anti-cancer
compounds called PPM1D (protein phosphatase magnesium-dependent 1 d)
inhibitors.

Work carried out at the Breakthrough Breast Cancer Research Centre
and at the Cancer Research UK Centre for Cancer Therapeutics, both of
which are at The Institute, showed that these compounds inhibit PPM1D
and selectively kill cells that over-express this phosphatase.
Over-expression of PPM1D occurs in many cases of cancer, and can be
readily detected. PPM1D inhibitors could therefore have potential as
highly targeted treatments for patients whose cancers are known to
express the phosphatase.

Antisoma plans to continue the preclinical development of PPM1D
inhibitors from The Institute's pipeline. Antisoma and The Institute
have also formed a collaboration to explore further the potential of
PPM1D-based approaches to cancer treatment. This work will continue
to take place at the Breakthrough Breast Cancer Research Centre and
the Cancer Research UK Centre for Cancer Therapeutics.

Antisoma will make an immediate upfront payment and fund certain
research at The Institute. Further payments will be made on
achievement of development and regulatory milestones, and royalties
will be paid on any sales of compounds resulting from the
collaboration.

Director of the Breakthrough Breast Cancer Research Centre at The
Institute, Professor Alan Ashworth, said: "This research marks
another step forward in our understanding of the basic biology
involved in the development of some cancers, and highlights the need
to develop treatments targeting the specific biology of different
tumours.

"This research exemplifies the ethos of the Breakthrough Breast
Cancer Research Centre - working in partnership with other
organisations to progress cutting-edge scientific research into
patient benefit. We look forward to continuing our research into
PPM1D inhibitors with Antisoma with the eventual aim of taking this
approach into clinical trials."

Professor Paul Workman, Director of the Cancer Research UK Centre for
Cancer Therapeutics at The Institute, said: "A partnership such as
this is crucial in allowing us to take this discovery from laboratory
to patients much faster than we could achieve on our own.

"Scientists at The Institute have discovered compounds which block
the effects of PPM1D, causing cancerous cells to self-destruct.
Through our partnership with Antisoma we hope to take the next step
towards developing a new drug treatment for cancer"

Antisoma's Chief Executive Officer, Glyn Edwards, said: "We are
delighted to be working with one of the world's leading cancer
research institutions. The Institute's PPM1D inhibitors are another
promising addition to our preclinical portfolio. They fit with our
strategy of acquiring a diverse range of novel preclinical compounds
with potential to add value to our clinical pipeline in the future."

[davenic] 30/9/2008 11:43

London, UK, and Cambridge, MA: 30 September 2008 - Cancer drug
developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that
it has started a phase II trial evaluating the addition of AS1402 to
the endocrine (hormonal) therapy letrozole in post-menopausal women
receiving first-line treatment for advanced breast cancer.

Approximately 110 patients will be randomly assigned to receive
either letrozole plus AS1402 or standard treatment with letrozole
alone. The safety of the AS1402-letrozole combination will be
evaluated and its efficacy compared with that of letrozole alone.
Measures of efficacy will include response rates, time to tumour
progression, progression-free survival and clinical benefit rate.
Final results are expected in 2010.

The phase II trial builds on a phase I study in patients with heavily
pre-treated breast cancer, which showed that AS1402 monotherapy was
well-tolerated and was associated with prolonged stable disease in a
number of patients.

AS1402 targets a cancer-associated form of the cell-surface protein
MUC1. This form is found in approximately 90% of breast cancers and
in a wide range of other tumours. Tissue culture studies have shown
that AS1402 binds to MUC1 on cancer cells and leads to their
destruction by antibody-dependent cellular cytotoxicity (ADCC), a
process involving recruitment of the immune system. Recent studies
have shown that MUC1 up-regulates the oestrogen signalling pathway
targeted by endocrine therapies. This provides a particular rationale
for combining AS1402 with letrozole in Antisoma's phase II trial.

Hospitals in the US, Russia, Ukraine, Poland and France are taking
part in the phase II study. The trial's Principal Investigator,
Professor Nuhad Ibrahim, of the MD Anderson Cancer Center, University
of Texas, said: "There is a clear rationale for testing AS1402 in
this group of breast cancer patients, and we are pleased to be
participating in this well-designed study."

Antisoma's Chief Operating Officer, Dr Ursula Ney, added: "Worldwide,
over 90,000 women each year receive endocrine treatment for advanced
breast cancer, so many patients could benefit from any add-on therapy
that improved outcomes in this setting. Our phase II study rigorously
tests the value of adding AS1402 to endocrine treatment and, if
positive, will provide a firm basis for progress to a pivotal phase
III trial in breast cancer."

[bluechef] 24/9/2008 13:08

Not sure why were still rock bottom, while other pharmas with late stage failures are on our heels. This may make interesting reading.
"At some point pharma companies say, 'Why buy licences to these drugs [from biotech groups] and deal with milestone payments when we can buy the whole company?' " said Robin Davison, an analyst at Edison Investment Research.

After its positive results on Thursday, Antisoma could become the next attractive takeover target, especially for its development partner Novartis. But big pharma takes a conservative approach to biotech investing and any potential suitor would probably await the outcome of Antisoma's lung cancer drug trials.

Similarly Sanofi-Aventis could turn its eye to Oxford BioMedica, with which it is developing a potential blockbuster in Trovax, a cancer drug. But Oxford BioMedica suffered a major setback this year when a safety board halted human vaccination testing of Trovax.

In both cases, the hot market for potential cancer drugs could make the target more attractive.

[davenic] 22/9/2008 13:55

About time this moved up

[divestor] 19/9/2008 11:27

Buys they may be but the share price is falling on virtually no sells. Any ideas?

[davenic] 19/9/2008 09:17

Nice few 250k buys come in

[pharmacist08] 18/9/2008 22:19

results are great at bottom of range analysts put for exceptional.

will see buy ins tomorrow as ftse rises